Track DYAI and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$42.95M
Enterprise Value$41.49M
Revenue (TTM)$4.02M
Net Income (TTM)-$7.29M
Free Cash Flow (TTM)-$5.72M
Financial Health
Cash$6.52M
Net Debt-$1.46M
Debt Ratio0.65
Debt to Equity-12.39
Interest Coverage-17.51
Valuation (TTM)
Price to Sales10.69
Price to Earnings-5.89
EV to EBITDA-5.81
Price to Book-105.34
Price to Free Cash Flow-7.51
Margins (TTM)
Gross Profit Margin72.75%
EBITDA Margin-177.80%
Operating Income Margin-175.59%
Net Income Margin-181.47%
Free Cash Flow Margin-142.25%
Returns (5Y Avg)
Return on Invested Capital-63.12%
Return on Assets-47.75%
Return on Equity-221.44%
Return on Total Capital-63.12%
Return on Capital Employed-99.96%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue14.04%
Diluted EPS1.94%
Total Debt110.30%
Capital Expenditures-19.73%
Free Cash Flow3.46%
CAGR (3Y)
Revenue1.79%
Diluted EPS3.70%
Total Debt1000.00%
Capital Expenditures-44.97%
Free Cash Flow1000.00%
CAGR (1Y)
Revenue-11.59%
Diluted EPS-2.69%
Total Debt0.58%
Capital Expenditures-80.00%
Free Cash Flow-100.00%
$1.51+$0.30|+19.87%
Last updated: Jul 21, 2:19 PM ET
52W High$1.35
52W Low$0.65
50D SMA$0.84
200D SMA$0.89
Volume544.86K
Dyadic International Inc
1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094
IPO
2004
Employees
5
Industry
Biotechnology
Sector
Healthcare
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20250+1
1
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0